The Novolizer®: Overcoming inherent problems of dry powder inhalers

Respiratory Medicine

Volumn 98, Issue SUPPL. A, 2004, Pages

  Kohler, Dieter ^a  

^a KRANKENHAUS KLOSTER GRAFSCHAFT   (Germany)

Author keywords

Compliance; Cost effective; Drug deposition; Intrinsic resistance; Multiple feedback mechanism; Novolizer

Indexed keywords

BUDESONIDE; CORTICOSTEROID; SALBUTAMOL; ANTIASTHMATIC AGENT;

ACCURACY; ACOUSTIC REFLEX; AEROSOL; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG QUALITY; DRY POWDER; FEEDBACK SYSTEM; FLOW RATE; HUMAN; INSPIRATORY CAPACITY; PARTICLE SIZE; PATIENT COMPLIANCE; POWDER INHALER; PRIORITY JOURNAL; RELIABILITY; TASTE; VISUAL SYSTEM; COST BENEFIT ANALYSIS; ECONOMICS; EQUIPMENT DESIGN; METERED DOSE INHALER;

ANTI-ASTHMATIC AGENTS; ASTHMA; COST-BENEFIT ANALYSIS; EQUIPMENT DESIGN; HUMANS; METERED DOSE INHALERS; PATIENT COMPLIANCE;

EID: 2342535881     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2004.02.005     Document Type: Article

References (15)

1. Global strategy for asthma management and prevention. NHLBI/WHO workshop report, NIH publication No. 95-3659. Bethesda, MD: National Institute of Health; 2002.
2. Giraud V, Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur Respir J 2002;19:246-51.
3. Köhler D. Novolizer: the new technology for the management of asthma therapy. Curr Opin Pulm Med 2003;9(Suppl 1):S11-6.
4. Fyrnys B, Stang N, Wolf-Heuss E. Stability and performance characteristics of a budesonide powder for inhalation with a novel dry powder inhaler device. Curr Opin Pulm Med 2001;7(Suppl 1):S7-11.
5. Newman S, Pitcairn G, Hirst P, et al. Scintigraphic comparison of budesonide deposition from two dry powder inhalers. Eur Respir J 2000;16:178-83.
6. Meakin B, Cainey J, Woodcock P. Effect of exposure to humidity on terbutaline delivery from turbuhaler dry powder inhalation devices. Eur Respir J 1993;6:760-1.
7. Vegis P. The challenges of microbiological control in new generation powder delivery devices. In: Dalby R, Byron P, Farr S, Peart J, editors. Respiratory drug delivery VII. Raleigh, NC: Amy David Serentec Press; 2000. p. 125-9.
8. Berner B, Fyrnys B, deBoer A. ASTA Medica's innovative multidose dry powder inhaler: operation and performance. Proceedings of 46th Annual Congress of APV/APGI, 3-6 April 2000. p. 781-2.
9. Everard M, Devadason S, Souef P. Flow early in the inspiratory manoeuvre affects the aerosol particle size distribution from a Turbuhaler. Respir Med 1997;91:624-8.
10. Kunkel G, Chuchalin A. Therapeutic equivalence of the Sofotec Novolizer to established standard devices in COPD and asthma. Curr Opin Pulm Med 2001;7(Suppl 1):S15-7.
11. Leupold W, Vogelberg C, Metzenauer P, Conrad F, Hermann R. Clinical evaluation of the peak inspiratory flow generated by asthmatic children through the Novolizer. Eur Respir J 2002;20:430S.
12. Erickson S, Horton A, Kirking D. Assessing Metered-dose inhaler technique: comparison of observation vs. patient self-report. J Asthma 1998;35:575-83.
13. Plaza V, Sanchis J. Medical personnel and patient skill in the use of metered dose inhalers: a multicentric study. CESEA Group. Respiration 1998;65:195-8.
14. Jonasson G, Carlsen K, Mowinckel P. Drug adherence in a long term clinical study. Arch Dis Child 2000;83:330-3.
15. Cochrane M, Bala M, Downs K, Mauskopf J, Ben-Joseph R. Inhaled corticosteroids for asthma therapy; patient compliance, devices and inhalation technique. Chest 2000; 117:542-50.